Catalina Trejo‐Becerril

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce et al. · Annals of Oncology · 2007 · 249 citations

Chemotherapy Resistance, Medicine, Pharmacology +7

Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.

Blanca Segura-Pacheco, Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas et al. · PubMed · 2003 · 206 citations

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

Pilar Zambrano, Blanca Segura-Pacheco, Enrique Pérez‐Cárdenas et al. · BMC Cancer · 2005 · 150 citations · Full text

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer

Claudia Arce, Carlos Pérez‐Plasencia, Aurora González‐Fierro et al. · PLoS ONE · 2006 · 144 citations · Full text

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

Alma Chávez‐Blanco, Carlos Pérez‐Plasencia, Enrique Pérez‐Cárdenas et al. · Cancer Cell International · 2006 · 142 citations · Full text